CR11295A - 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos - Google Patents

2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Info

Publication number
CR11295A
CR11295A CR11295A CR11295A CR11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A
Authority
CR
Costa Rica
Prior art keywords
anilinopurin
onas
ttk
treatment
proliferative disorders
Prior art date
Application number
CR11295A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Ianin Simpson
Richard Andrew Ward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11295A publication Critical patent/CR11295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos quimicos de la formula (I) o una sal farmaceutica aceptable de estos, que poseen actividad inhibitoria frente a la cinasa del punto de control del huso.
CR11295A 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos CR11295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
CR11295A true CR11295A (es) 2010-05-28

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11295A CR11295A (es) 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Country Status (19)

Country Link
US (1) US20110118238A1 (es)
EP (1) EP2212326A1 (es)
JP (1) JP2010536841A (es)
KR (1) KR20100057650A (es)
CN (1) CN103298814A (es)
AU (1) AU2008290330A1 (es)
BR (1) BRPI0815709A2 (es)
CA (1) CA2696200A1 (es)
CO (1) CO6260060A2 (es)
CR (1) CR11295A (es)
DO (1) DOP2010000064A (es)
EA (1) EA201000341A1 (es)
EC (1) ECSP10010034A (es)
MX (1) MX2010002115A (es)
NI (1) NI201000032A (es)
NZ (1) NZ584138A (es)
SV (1) SV2010003491A (es)
WO (1) WO2009024824A1 (es)
ZA (1) ZA201001193B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
CA2821819A1 (en) * 2010-12-17 2012-06-21 Marcus Koppitz 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
ES2544609T3 (es) * 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP2013545776A (ja) * 2010-12-17 2013-12-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CA2821817A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
RS54044B1 (sr) 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh Triazolopiridini
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2914516A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
AP2015008898A0 (en) 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
JP6883653B2 (ja) 2016-12-20 2021-06-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
ES2909234T3 (es) * 2016-12-21 2022-05-05 Ono Pharmaceutical Co Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CA3130478A1 (en) * 2019-03-13 2020-09-17 Voronoi Co., Ltd. Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient
AU2021256235B2 (en) * 2020-04-17 2024-05-09 Kangbaida (Sichuan) Biotechnology Co., Ltd. Imidazolidinone derivatives and medical use thereof
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN116917288B (zh) * 2021-03-22 2026-04-14 成都赜灵生物医药科技股份有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
TWI823531B (zh) * 2021-08-23 2023-11-21 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物或者其立體異構體的製備方法及其中間體
US20240391921A1 (en) * 2021-09-23 2024-11-28 Chengdu Baiyu Pharmaceutical Co., Ltd. Crystal form of imidazolinone derivative
EP4556009A1 (en) * 2022-07-13 2025-05-21 Kangbaida (Sichuan) Biotechnology Co., Ltd. Use of imidazolinone derivative in combination with radiotherapy in treatment of tumors
WO2024017220A1 (zh) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用
KR20250140519A (ko) * 2022-12-13 2025-09-25 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 이미다졸리논 화합물의 약학적 제제, 이의 제조방법, 및 이의 용도
TW202513059A (zh) * 2023-09-21 2025-04-01 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用及治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846408B1 (en) * 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
NZ584138A (en) 2011-10-28
CA2696200A1 (en) 2009-02-26
EA201000341A1 (ru) 2010-10-29
AU2008290330A1 (en) 2009-02-26
KR20100057650A (ko) 2010-05-31
EP2212326A1 (en) 2010-08-04
NI201000032A (es) 2010-12-07
DOP2010000064A (es) 2010-03-31
MX2010002115A (es) 2010-06-01
ZA201001193B (en) 2010-10-27
CN103298814A (zh) 2013-09-11
CO6260060A2 (es) 2011-03-22
SV2010003491A (es) 2010-07-06
BRPI0815709A2 (pt) 2017-06-13
JP2010536841A (ja) 2010-12-02
US20110118238A1 (en) 2011-05-19
ECSP10010034A (es) 2010-04-30
WO2009024824A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CR11295A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
EA201170872A1 (ru) Ингибиторы протеинкиназы
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
BR112016024533A2 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
BR112016024484A2 (pt) derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
BR112016023967A2 (pt) derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
MX2019010595A (es) Derivados de pirrolotriazina como inhibidores de cinasas.
CU20100038A7 (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)